Until recently metastatic melanoma was a disease with limited treatment options and a poor prognosis. However, new promising products have been developed. Ipilimumab, a full human anti-cytotoxic T-lymphocyte antigen-4 antibody, has shown improved survival in several clinical trials and is now a part of the standard treatment options for this disease in Denmark. In this case report we present a 78-year-old man with metastatic melanoma who had complete remission after treatment with ipilimumab.